Vis enkel innførsel

dc.contributor.authorVisser, Nicole C.M.en_US
dc.contributor.authorvan der Putten, Louis J.M.en_US
dc.contributor.authorvan Egerschot, Alexen_US
dc.contributor.authorvan de Vijver, Koen K.en_US
dc.contributor.authorSantacana, Mariaen_US
dc.contributor.authorBronsert, Peteren_US
dc.contributor.authorHirschfeld, Marcen_US
dc.contributor.authorColas, Evaen_US
dc.contributor.authorGil-Moreno, Antonioen_US
dc.contributor.authorGarcia, Angelen_US
dc.contributor.authorMancebo, Gemmaen_US
dc.contributor.authorAlameda, Francescen_US
dc.contributor.authorKrakstad, Camillaen_US
dc.contributor.authorTangen, Ingvild Løbergen_US
dc.contributor.authorHuvila, Juttaen_US
dc.contributor.authorSchrauwen, Stefanieen_US
dc.contributor.authorKoskas, Martinen_US
dc.contributor.authorWalker, Francineen_US
dc.contributor.authorWeinberger, Viten_US
dc.contributor.authorMinar, Lubosen_US
dc.contributor.authorHausnerova, Jitkaen_US
dc.contributor.authorSnijders, Marc P.L.M.en_US
dc.contributor.authorvan den Berg-van Erp, Saskiaen_US
dc.contributor.authorMatias-Guiu, Xavieren_US
dc.contributor.authorTrovik, Joneen_US
dc.contributor.authorAmant, Frédéricen_US
dc.contributor.authorMassuger, Leon F.A.G.en_US
dc.contributor.authorBulten, Johanen_US
dc.contributor.authorPijnenborg, Johanna M.A.en_US
dc.date.accessioned2020-05-08T11:00:06Z
dc.date.available2020-05-08T11:00:06Z
dc.date.issued2019
dc.PublishedVisser NC, van der Putten, van Egerschot, van de Vijver, Santacana M, Bronsert P, et al. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human Pathology. 2019;89:90-98eng
dc.identifier.issn1532-8392
dc.identifier.issn0046-8177
dc.identifier.urihttps://hdl.handle.net/1956/22138
dc.description.abstractDiscrimination between low- and high-grade endometrial carcinomas (ECs) is clinically relevant but can be challenging for pathologists, with moderate interobserver agreement. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofoetal protein that is associated with nonendometrioid endometrial carcinomas but has been limited studied in endometrioid carcinomas. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs and its added value to L1CAM. IMP3 and L1CAM expression was assessed in tumors from 378 patients treated for EC at 1 of 9 participating European Network for Individualised Treatment of Endometrial Cancer centers. IMP3 was expressed in 24.6% of the tumors. In general, IMP3 was more homogeneously expressed than L1CAM. IMP3 expression was significantly associated with advanced stage, nonendometrioid histology, grade 3 tumors, deep myometrial invasion, lymphovascular space invasion, distant recurrences, overall mortality, and disease-related mortality. Simultaneous absence of IMP3 and L1CAM expression showed the highest accuracy for identifying low-grade carcinomas (area under the curve 0.766), whereas simultaneous expression of IMP3 and L1CAM was strongly associated with high-grade carcinomas (odds ratio 19.7; 95% confidence interval 9.2-42.2). Even within endometrioid carcinomas, this combination remained superior to IMP3 and L1CAM alone (odds ratio 8.6; 95% confidence interval 3.4-21.9). In conclusion, IMP3 has good diagnostic value and together with L1CAM represents the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression.en_US
dc.language.isoengeng
dc.publisherElseviereng
dc.rightsAttribution-Non Commercial-No Derivatives CC BY-NC-NDeng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/eng
dc.titleAddition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration studyen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2020-01-21T13:45:32Z
dc.description.versionacceptedVersionen_US
dc.rights.holderCopyright 2019 Elsevier
dc.identifier.doihttps://doi.org/10.1016/j.humpath.2019.04.014
dc.identifier.cristin1715990
dc.source.journalHuman Pathology
dc.relation.projectKreftforeningen: 190202
dc.relation.projectNorges forskningsråd: 273280


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-Non Commercial-No Derivatives CC BY-NC-ND
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-Non Commercial-No Derivatives CC BY-NC-ND